US2022401478A1PendingUtilityA1

Ebv-specific immune cells

52
Assignee: BAYLOR COLLEGE MEDICINEPriority: Apr 18, 2019Filed: Apr 9, 2020Published: Dec 22, 2022
Est. expiryApr 18, 2039(~12.7 yrs left)· nominal 20-yr term from priority
Inventors:Cliona M. RooneySandhya Sharma
A61P 35/00C07K 14/005C12N 2501/998C12N 2710/16234C12N 2501/51C12N 2710/16122C07K 14/05C12N 2710/16222A61K 39/12C12N 2502/1114C12N 5/0638A61K 35/17A61K 40/11A61K 40/46A61K 40/4224A61K 2239/48A61K 39/0011C12N 5/0634
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for generating/expanding populations of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen are disclosed, the methods comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens. Also disclosed are populations of immune cells comprising immune cells specific for an EBV lytic antigen expanded according to such methods, and uses thereof.

Claims

exact text as granted — not AI-modified
1 . A method for generating or expanding a population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen, comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens. 
     
     
         2 . The method according to  claim 1 , wherein the method further comprises re-stimulating the immune cells specific for an EBV lytic antigen by contacting them with APCs presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens. 
     
     
         3 . A method for generating or expanding a population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen and immune cells specific for an EBV latent antigen, comprising stimulating immune cells specific for an EBV lytic antigen and immune cells specific for an EBV latent antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of one or more EBV latent antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of one or more EBV latent antigens. 
     
     
         4 . The method according to  claim 3 , wherein the method further comprises re-stimulating the immune cells specific for an EBV lytic antigen and the immune cells specific for an EBV latent antigen by contacting them with APCs presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens, and one or more peptides corresponding to all or part of an EBV latent antigen. 
     
     
         5 . The method according to any one of  claims 1  to  4 , wherein the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BXLF1, BALF1, BALF2, BGLF5, BHRF1, BNLF2A, BNLF2B, BHLF1, BLLF2, BKRF4, BMRF2, BALF4, BILF1, BILF2, BNFR1, BVRF2, BALF3, BALF5 and BDLF3. 
     
     
         6 . The method according to any one of  claims 1  to  5 , wherein the one or more EBV lytic antigens are selected from BZLF1, BRLF1, BMLF1, BMRF1, BALF2, BNLF2A, BNLF2B, BMRF2 and BDLF3. 
     
     
         7 . The method according to any one of  claims 3  to  6 , wherein the one or more EBV latent antigens are selected from EBNA1, EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C, BARF1, LMP1, LMP2A and LMP2B. 
     
     
         8 . The method according to any one of  claims 3  to  7 , wherein the one or more EBV latent antigens are selected from EBNA1, LMP1, LMP2A and LMP2B. 
     
     
         9 . The method according to any one of  claims 1  to  8 , wherein the PBMCs are PBMCs depleted of CD45RA-positive cells. 
     
     
         10 . An isolated population of immune cells obtained or obtainable by a method according to any one of  claims 1  to  9 . 
     
     
         11 . An isolated population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen. 
     
     
         12 . An isolated population of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen and immune cells specific for an EBV latent antigen. 
     
     
         13 . A pharmaceutical composition comprising an isolated population of immune cells according to any one of  claims 10  to  12 . 
     
     
         14 . An isolated population of immune cells according to any one of  claims 10  to  12 , or a pharmaceutical composition according to  claim 13 , for use in a method of treatment or prevention of a disease or disorder. 
     
     
         15 . Use of isolated population of immune cells according to any one of  claims 10  to  12 , or a pharmaceutical composition according to  claim 13 , in the manufacture of a medicament for use in a method of treatment or prevention of a disease or disorder. 
     
     
         16 . A method for treating or preventing a disease or disorder associated, comprising administering an isolated population of immune cells according to any one of  claims 10  to  12 , or a pharmaceutical composition according to  claim 13 , to a subject. 
     
     
         17 . The isolated population of immune cells or pharmaceutical composition for use according to  claim 14 , the use according to  claim 15 , or the method according to  claim 16 , wherein the disease or disorder is a disease or disorder associated with EBV infection. 
     
     
         18 . The isolated population of immune cells or pharmaceutical composition for use according to  claim 14 , the use according to  claim 15 , or the method according to  claim 16 , wherein the disease or disorder is a cancer. 
     
     
         19 . The isolated population of immune cells or pharmaceutical composition for use, the use, or the method according to  claim 17 , wherein the disease or disorder associated with EBV infection is an EBV-associated cancer. 
     
     
         20 . The isolated population of immune cells or pharmaceutical composition for use, the use, or the method according to  claim 18 , wherein the cancer is an EBV-associated cancer. 
     
     
         21 . The isolated population of immune cells or pharmaceutical composition for use, the use, or the method according to  claim 19  or  claim 20 , wherein the EBV-associated cancer is selected from EBV-positive lymphoma, EBV-positive nasopharyngeal carcinoma, and EBV-positive gastric carcinoma. 
     
     
         22 . A method for killing a cell infected with EBV, comprising contacting a cell infected with EBV with an isolated population of immune cells according to any one of  claims 10  to  12 , or a pharmaceutical composition according to  claim 13 . 
     
     
         23 . Use of an isolated population of immune cells according to any one of  claims 10  to  12 , or a pharmaceutical composition according to  claim 13  to kill a cell infected with EBV. 
     
     
         24 . A method for killing a cancer cell, comprising contacting a cancer cell with an isolated population of immune cells according to any one of  claims 10  to  12 , or a pharmaceutical composition according to  claim 13 . 
     
     
         25 . Use of an isolated population of immune cells according to any one of  claims 10  to  12 , or a pharmaceutical composition according to  claim 13  to kill a cancer cell. 
     
     
         26 . The method or use according to  claim 24  or  claim 25 , wherein the cancer cell is infected with EBV.

Join the waitlist — get patent alerts

Track US2022401478A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.